HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vega, G. L. Articles by Grundy, S. M. Search for Related Content PubMed PubMed Citation Articles by Vega, G. L. Articles by Grundy, S. M. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 25, 580-592, Copyright © 1984 by Lipid Research, Inc.

ARTICLES

Comparison of apolipoprotein B to cholesterol in low density lipoproteins of patients with coronary heart disease

GL Vega and SM Grundy

This study was carried out to determine whether patients with coronary heart disease (CHD) have an unusually high level of apolipoprotein B (apoB) relative to cholesterol (C) in low density lipoproteins (LDL). Seven groups of men were studied. Seventy-two with normolipidemia (NLP) had CHD documented on clinical grounds; another 34 NLP patients had proven coronary artery disease (CAD) by angiography (greater than 50% occlusion of two or three coronary arteries). Another group of 37 with documented CHD had hypertriglyceridemia (HTG), and still another 25 with HTG had proven CAD. Three normolipidemic control groups consisted of 30 healthy young men, 40 healthy middle-aged men, and 35 hypertensive men. In normolipidemic CHD and CAD patients, plasma LDL-C averaged 142 +/- 37 (SD) and 136 +/- 32 mg/dl, respectively; in HTG patients with CHD and CAD, LDL-C levels were 137 +/- 37 and 127 +/- 34 mg/dl, respectively. These values were near those of hypertensive controls (141 +/- 31 mg/dl), but higher than middle-aged and younger healthy controls (118 +/- 32 and 106 +/- 26 mg/dl, respectively). Levels of LDL-apoB followed a similar pattern: CHD-NLP (88 +/- 25 mg/dl), CAD-NLP (83 +/- 25 mg/dl), CHD-HTG (94 +/- 30 mg/dl), CAD-HTG (89 +/- 25 mg/dl), hypertensive controls (89 +/- 24 mg/dl), middle-aged controls (80 +/- 25 mg/dl) and younger controls (58 +/- 14 mg/dl). Normolipidemic patients with CHD and CAD did not have higher LDL-C and LDL-apoB levels than hypertensive and normotensive controls. HTG patients with CHD and CAD however tended to have higher LDL-apoB levels, and their LDL-apoB/C ratios were higher on average than normal. Nevertheless, among all coronary groups, there were no sizable subgroups with elevated LDL-apoB; only about 11% of all coronary patients had LDL-apoB levels over 120 mg/dl (compared to 8% for normo- and hypertensive controls of middle age). The data of this study therefore suggest that LDL-apoB may not prove to be a better indicator of coronary risk in normolipidemic people, but LDL-apoB could be a superior predictor of risk in HTG patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Martin-Jadraque, F. Tato, J. M. Mostaza, G. L. Vega, and S. M. Grundy Effectiveness of Low-Dose Crystalline Nicotinic Acid in Men With Low High-Density Lipoprotein Cholesterol Levels Arch Intern Med, May 27, 1996; 156(10): 1081 - 1088. [Abstract] [PDF]

				R. J. Valentine, P. A. Grayburn, G. L. Vega, and S. M. Grundy Lp(a) Lipoprotein Is an Independent, Discriminating Risk Factor for Premature Peripheral Atherosclerosis Among White Men Arch Intern Med, April 11, 1994; 154(7): 801 - 806. [Abstract] [PDF]

				G. L. Vega and S. M. Grundy Primary Hypertriglyceridemia With Borderline High Cholesterol and Elevated Apolipoprotein B Concentrations: Comparison of Gemfibrozil vs Lovastatin Therapy JAMA, December 5, 1990; 264(21): 2759 - 2763. [Abstract] [PDF]

				S. M. Grundy and G. L. Vega Role of Apolipoprotein Levels in Clinical Practice Arch Intern Med, August 1, 1990; 150(8): 1579 - 1582. [Abstract] [PDF]

				G. L. Vega and S. M. Grundy Management of Primary Mixed Hyperlipidemia With Lovastatin Arch Intern Med, June 1, 1990; 150(6): 1313 - 1319. [Abstract] [PDF]

				G. L. Vega and S. M. Grundy Comparison of Lovastatin and Gemfibrozil in Normolipidemic Patients With Hypoalphalipoproteinemia JAMA, December 8, 1989; 262(22): 3148 - 3153. [Abstract] [PDF]

				G. L. Vega and S. M. Grundy Gemfibrozil Therapy in Primary Hypertriglyceridemia Associated With Coronary Heart Disease: Effects on Metabolism of Low-Density Lipoproteins JAMA, April 26, 1985; 253(16): 2398 - 2403. [Abstract] [PDF]